Education
About Us
Working with TipRanks
Follow Us
Alkermes (ALKS)
NASDAQ:ALKS
Alks 2680 Dose 1, Alks 2680 Dose 2, Alixorexton
Narcolepsy Type 1
Phase III
Not Yet Recruiting
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Mar 03, 2026
―
Alks 2680
Narcolepsy Type 1
Phase II
Completed
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
Apr 02, 2024
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Alkermes (ALKS) have in its pipeline
ALKS is currently developing the following drugs: Alks 2680 Dose 1, Alks 2680 Dose 2, Alixorexton, Alks 2680, Alks 2680, 4Mg, Alks 2680, 6Mg, Alks 2680, 8Mg, Alks 2680, 10Mg, Alks 2680, 14Mg, Alks 2680, 18Mg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.